NALP13 Inhibitors
NALP13 inhibitors aim to downregulate the NOD-like receptor signaling pathway by targeting various key components. For instance, MCC950, a potent NLRP3 inflammasome inhibitor, blocks ASC oligomerization, a critical step in inflammasome formation. Chemicals like Parthenolide and Bay 11-7082 inhibit the NF-κB pathway by suppressing IκB kinase or blocking IκB phosphorylation, respectively. NF-κB is a crucial transcription factor for many NLR-dependent genes, and its inhibition can thereby suppress NALP13 at the transcriptional level.
Caspase-1 inhibitors, such as Z-YVAD-FMK and VX-765, block the maturation of proinflammatory cytokines IL-1β and IL-18. Since NLRs often contribute to the activation of caspase-1 through inflammasome formation, inhibiting this enzyme could thwart NALP13's role in this process. In addition, inhibitors of the ATP-sensitive potassium channel, like Glyburide, modulate ion flux that is critical for NLRP3 inflammasome activation and might have a similar effect on NALP13. Through understanding the mechanistic aspects of these inhibitors, one can infer how they would interfere with NALP13 function, whether by stalling its inflammasome assembly, affecting its transcription, or blocking downstream signaling events.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
NF-κB pathway inhibitor. Suppresses IκB kinase, leading to a reduction in NF-κB translocation to the nucleus, affecting NLRs like NALP13 indirectly. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
IL-1 receptor antagonist. Prevents IL-1β signaling, downregulating NLR-mediated inflammation, affecting NALP13 function indirectly if it contributes to IL-1β release. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
ATP-sensitive potassium channel blocker. Modulates ion flux involved in NLRP3 activation, potentially influencing NALP13. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Inhibits NF-κB by blocking IκB phosphorylation. This disrupts the activation of downstream NLR-dependent pathways, indirectly affecting NALP13. | ||||||
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
Caspase-1 inhibitor that blocks IL-1β and IL-18 production, potentially affecting NALP13 if it has a role in inflammasome activation. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $40.00 | 7 | |
NF-κB inhibitor that suppresses the translocation and DNA binding of NF-κB, affecting NLRs like NALP13 if they are downstream of NF-κB. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $33.00 $64.00 | 11 | |
NF-κB inhibitor that prevents IκB degradation, thereby disrupting NLR activation and potentially modulating NALP13 function. | ||||||
Tanshinone IIA | 568-72-9 | sc-200932 sc-200932A | 5 mg 25 mg | $88.00 $316.00 | 22 | |
NF-κB inhibitor. Inhibits IκB phosphorylation and NF-κB nuclear translocation, potentially affecting NALP13. | ||||||